Medtronic (MDT) EBITDA (2014 - 2026)

Medtronic (MDT) has 13 years of EBITDA data on file, last reported at $1.9 billion in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 30.43% year-over-year to $1.9 billion; the trailing twelve-month figure through Apr 2026 stood at $6.5 billion (up 8.61% YoY), and the FY2026 full-year result was $6.5 billion, up 8.6% from the prior year.
• EBITDA advanced to $1.9 billion in Q2 2026, from $1.5 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.9 billion in Q2 2026 to a low of $1.1 billion in Q2 2024.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA tumbled 32.72% in 2024 and surged 36.37% in 2025, its largest moves.
• Tracing MDT's EBITDA over 5 years: stood at $1.4 billion in 2022, then slipped by 4.56% to $1.3 billion in 2023, then advanced by 19.03% to $1.6 billion in 2024, then rose by 5.71% to $1.7 billion in 2025, then grew by 11.09% to $1.9 billion in 2026.
• Business Quant data shows MDT's EBITDA at $1.9 billion in Q2 2026, $1.5 billion in Q1 2026, and $1.7 billion in Q4 2025.